Mixed dementia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:30:39 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Mixed dementia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Benefits of Amyloid PET Imaging with Florbetaben (18F) and Flutemetamol (18F) for Patients with Various Types of Dementia https://clinicaltrials.eu/trial/study-on-the-benefits-of-amyloid-pet-imaging-with-florbetaben-18f-and-flutemetamol-18f-for-patients-with-various-types-of-dementia/ Wed, 29 Apr 2026 14:26:26 +0000 https://clinicaltrials.eu/trial/study-on-the-benefits-of-amyloid-pet-imaging-with-florbetaben-18f-and-flutemetamol-18f-for-patients-with-various-types-of-dementia/ This clinical trial is focused on studying the benefits of using a special type of brain scan called amyloid PET imaging for people with different types of dementia. Dementia is a condition that affects memory, thinking, and the ability to perform everyday activities. The study includes various forms of dementia, such as Alzheimer’s disease, vascular dementia, and dementia related to other conditions like Parkinson’s disease and HIV. The trial aims to see if amyloid PET imaging can provide better information compared to standard methods without this imaging.

Participants in the study will receive either the amyloid PET imaging or standard diagnostic procedures. The imaging involves using a solution for injection, such as Neuraceq or VIZAMYL, which contains substances like florbetaben (18F) or flutemetamol (18F). These substances help highlight certain areas of the brain during the scan. The study will observe how this imaging affects the management of daily activities and overall quality of life for those with dementia.

The trial will last for several weeks, with follow-up assessments to monitor changes in cognitive performance, quality of life, and any potential side effects. The goal is to determine if amyloid PET imaging can improve the understanding and treatment of dementia compared to current diagnostic methods. Participants will be monitored by healthcare professionals throughout the study to ensure their safety and well-being.

]]>